Preclinical News and Research

RSS

New recommendations for optimization, validation of the quantitative measurement of HBV cccDNA

Approximately 300 million people worldwide are chronically infected with the hepatitis B virus (HBV) and at high risk of developing liver cirrhosis or hepatocellular carcinoma.

6 Feb 2023

Study reveals mechanism of a previously unexplained type of cell death

A study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Cell Biology, details a previously unexplained type of cell death called disulfidptosis that could open the door for novel cancer therapeutic strategies.

6 Feb 2023

AAHI awarded a $9.9 million project to develop prototype intranasal bivalent influenza RNA vaccine candidate

The Access to Advanced Health Institute announced today that it has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium Other Transaction Authority to develop a prototype intranasal bivalent influenza RNA vaccine candidate based on AAHI's self-amplifying RNA (saRNA) platform that targets both pandemic A(H5N1) and A(H7N9) influenza virus pathogens.

6 Feb 2023

Experimental vaccine completely protects cynomolgus macaques against lethal Sudan virus

A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine.

3 Feb 2023

Study identifies a drug candidate for the treatment of fatty liver disease

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases.

3 Feb 2023

The effectiveness of intranasal COVID-19 vaccination in healthy adults

A recent study discusses the safety profiles and immunogenicity of the nasal BBV154 COVID-19 vaccine in healthy adults.

3 Feb 2023

Low-grade inflammation may cause early vascular damage and atherosclerosis in adolescents

Early vascular damage and atherosclerosis in adolescents may be caused by low-grade inflammation, a paper published in the Journal of Applied Physiology concludes.

3 Feb 2023

World Cancer Day 2023: Perspectives from The Institute of Cancer Therapeutics

To commemorate World Cancer Day, we spoke to a multidisciplinary team of researchers from The Institute of Cancer Therapeutics (ICT) based at the University of Bradford about their work in cancer research.

3 Feb 2023

Improving CAR-based-immunotherapies using a molecular anchor

Adding a molecular anchor to the key protein used to recognize cancer in cellular immunotherapies can make the treatments significantly more effective.

3 Feb 2023

Oncodesign Services looks to the future

As Oncodesign evolves into Oncodesign Services and begins its journey as an independent business, CEO Fabrice Viviani explains his hopes and plans for the company’s future.

From Oncodesign Services 3 Feb 2023

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, following the entry into exclusive negotiations on June 30, 2022.

From Oncodesign Services 3 Feb 2023

UC Davis launches new institute to advance basic knowledge of psychedelics and neurotherapeutics

The University of California, Davis has launched the Institute for Psychedelics and Neurotherapeutics to advance basic knowledge about the mechanisms of psychedelics and translate it into safe and effective treatments for diseases such as depression, post-traumatic stress disorder, addiction, Alzheimer's disease and Parkinson's disease, among others.

2 Feb 2023

Research reveals a candidate drug and biomarker to target uveal melanoma

Findings from an international research study involving Irish and Spanish patients reveal a candidate drug and biomarker that could be used to manage uveal melanoma.

2 Feb 2023

CuSTOM; Creating a healthier society by accelerating the translation of organoid technology

In this interview, we speak to Magdalena Kasendra at the CuSTOM Accelerator, about the organoid technology and how it has the power the revolutionize healthcare.

From Society for Laboratory Automation and Screening (SLAS) 1 Feb 2023

New nanomedicine delivery system offers some hope for treating peritoneal cancer

Peritoneal cancer is difficult to treat and has a poor survival prognosis. But a new and effective nanomedicine delivery system is offering some hope.

31 Jan 2023

Focused-ultrasound-mediated liquid biopsy improves detection of neurodegeneration biomarkers

Several progressive neurodegenerative disorders, including Alzheimer's disease, are defined by having tau proteins in the brain.

31 Jan 2023

New biomaterial allows for treating damaged tissue from the inside out

A new biomaterial that can be injected intravenously, reduces inflammation in tissue and promotes cell and tissue repair.

30 Jan 2023

Doctoral research presents predictive value of biomarkers for inflammatory bowel diseases

Under the supervision of four professors from the UMCG departments of Gastroenterology and Hepatology and Pathology and Medical Biology, Bourgonje conducted doctoral research on the predictive value of biomarkers for inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.

29 Jan 2023

Study identifies the DNA roots of resistance to targeted cancer therapy

A new clinical and preclinical study from UCLA Jonsson Comprehensive Cancer Center identifies the DNA roots of resistance to targeted cancer therapy, providing a possible strategy to address a vexing issue in cancer therapeutics.

26 Jan 2023

Study shows improved host health by modulating intestinal microbiota

Researchers presented intestinal microbiota modulation as a probable therapeutic option for diseases such as Crohn’s disease (CD).

26 Jan 2023

Preclinical News and Research

New recommendations for optimization, validation of the quantitative measurement of HBV cccDNA

Study reveals mechanism of a previously unexplained type of cell death

AAHI awarded a $9.9 million project to develop prototype intranasal bivalent influenza RNA vaccine candidate

Experimental vaccine completely protects cynomolgus macaques against lethal Sudan virus

Study identifies a drug candidate for the treatment of fatty liver disease

The effectiveness of intranasal COVID-19 vaccination in healthy adults

Low-grade inflammation may cause early vascular damage and atherosclerosis in adolescents

World Cancer Day 2023: Perspectives from The Institute of Cancer Therapeutics

Improving CAR-based-immunotherapies using a molecular anchor

Oncodesign Services looks to the future

ERES IV acquires a majority stake in Oncodesign Services

UC Davis launches new institute to advance basic knowledge of psychedelics and neurotherapeutics

Research reveals a candidate drug and biomarker to target uveal melanoma

CuSTOM; Creating a healthier society by accelerating the translation of organoid technology

New nanomedicine delivery system offers some hope for treating peritoneal cancer

Focused-ultrasound-mediated liquid biopsy improves detection of neurodegeneration biomarkers

New biomaterial allows for treating damaged tissue from the inside out

Doctoral research presents predictive value of biomarkers for inflammatory bowel diseases

Study identifies the DNA roots of resistance to targeted cancer therapy

Study shows improved host health by modulating intestinal microbiota

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics